The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1615
January 11, 2021
View Complete Issue         Table of Contents 2019 
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
January 11, 2021 (Issue: 1615)
The FDA has approved opicapone (Ongentys – Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an adjunct to carbidopa/levodopa in adults with Parkinson’s disease (PD) who experience...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
Article code: 1615c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.